Lantheus (NASDAQ:LNTH) Price Target Cut to $135.00

Lantheus (NASDAQ:LNTH) had its price objective dropped by analysts at Truist Financial from $141.00 to $135.00 in a research report issued on Thursday, Benzinga reports. The brokerage presently has a “buy” rating on the medical equipment provider’s stock. Truist Financial’s target price indicates a potential upside of 28.27% from the stock’s current price.

LNTH has been the topic of a number of other reports. StockNews.com lowered shares of Lantheus from a “buy” rating to a “hold” rating in a research report on Friday, May 3rd. Mizuho boosted their target price on shares of Lantheus from $90.00 to $100.00 and gave the stock a “buy” rating in a research note on Friday, May 3rd. SVB Leerink boosted their target price on shares of Lantheus from $106.00 to $127.00 and gave the stock an “outperform” rating in a research note on Thursday, July 11th. B. Riley boosted their target price on shares of Lantheus from $105.00 to $146.00 and gave the stock a “buy” rating in a research note on Thursday, July 25th. Finally, JMP Securities boosted their price target on shares of Lantheus from $100.00 to $130.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 10th. Two equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $119.71.

Lantheus Price Performance

NASDAQ:LNTH opened at $105.25 on Thursday. The firm has a market cap of $7.29 billion, a PE ratio of 16.07 and a beta of 0.51. Lantheus has a 12 month low of $50.20 and a 12 month high of $126.89. The company has a quick ratio of 4.55, a current ratio of 4.84 and a debt-to-equity ratio of 0.59. The company’s 50-day moving average price is $90.93 and its two-hundred day moving average price is $72.42.

Lantheus (NASDAQ:LNTH) last released its quarterly earnings results on Wednesday, July 31st. The medical equipment provider reported $1.61 EPS for the quarter, missing analysts’ consensus estimates of $1.68 by ($0.07). The firm had revenue of $394.10 million during the quarter, compared to analyst estimates of $382.12 million. Lantheus had a net margin of 33.72% and a return on equity of 54.10%. Lantheus’s quarterly revenue was up 22.5% on a year-over-year basis. During the same quarter last year, the firm earned $1.40 earnings per share. On average, equities analysts anticipate that Lantheus will post 6.46 EPS for the current fiscal year.

Insider Buying and Selling at Lantheus

In other Lantheus news, CAO Andrea Sabens sold 341 shares of the company’s stock in a transaction that occurred on Monday, May 13th. The shares were sold at an average price of $76.89, for a total value of $26,219.49. Following the completion of the sale, the chief accounting officer now owns 62,898 shares of the company’s stock, valued at $4,836,227.22. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Lantheus news, CAO Andrea Sabens sold 341 shares of the company’s stock in a transaction that occurred on Monday, May 13th. The shares were sold at an average price of $76.89, for a total value of $26,219.49. Following the completion of the sale, the chief accounting officer now owns 62,898 shares of the company’s stock, valued at $4,836,227.22. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Heinz Christoph Maeusli sold 18,373 shares of the company’s stock in a transaction that occurred on Tuesday, May 28th. The shares were sold at an average price of $79.19, for a total transaction of $1,454,957.87. Following the completion of the transaction, the director now owns 23,340 shares of the company’s stock, valued at approximately $1,848,294.60. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 44,799 shares of company stock valued at $3,769,262. Corporate insiders own 1.50% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Lisanti Capital Growth LLC acquired a new position in shares of Lantheus in the second quarter valued at approximately $6,253,000. Van ECK Associates Corp acquired a new position in Lantheus during the second quarter worth $2,960,000. International Assets Investment Management LLC acquired a new position in Lantheus during the second quarter worth $121,000. Principal Financial Group Inc. boosted its holdings in Lantheus by 18.1% during the second quarter. Principal Financial Group Inc. now owns 367,735 shares of the medical equipment provider’s stock worth $29,525,000 after purchasing an additional 56,432 shares during the last quarter. Finally, American Capital Advisory LLC acquired a new position in Lantheus during the second quarter worth $536,000. Institutional investors and hedge funds own 99.06% of the company’s stock.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.